Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia

被引：21

作者：

Choi, Eun-Ji ^{[1
]}

Lee, Je-Hwan ^{[1
]}

Lee, Jung-Hee ^{[1
]}

Park, Han-Seung ^{[1
]}

Ko, Sun-Hye ^{[1
]}

Hur, Eun-Hye ^{[1
]}

Moon, Juhyun ^{[1
]}

Goo, Bon-Kwan ^{[1
]}

Kim, Yeonhee ^{[2
]}

Seol, Miee ^{[1
]}

Lee, Young-Shin ^{[1
]}

Kang, Young-Ah ^{[1
]}

Jeon, Mijin ^{[1
]}

Woo, Ji Min ^{[1
]}

Lee, Kyoo-Hyung ^{[1
]}

机构：

[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Hematol, 88,Olymp Ro 43 Gil, Seoul 05505, South Korea

[2] Gilead Sci Inc, Seattle, WA USA

来源：

LEUKEMIA RESEARCH | 2018年 / 68卷

基金：

新加坡国家研究基金会;

关键词：

Acute myeloid leukemia; FLT3-ITD; Induction chemotherapy; Anthracycline; HIGH-DOSE DAUNORUBICIN; FLT3; INHIBITORS; AML; IDARUBICIN; COMBINATION; MIDOSTAURIN; SORAFENIB; MUTATIONS; EXPOSURE; STANDARD;

D O I：

10.1016/j.leukres.2018.03.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This retrospective analysis compared anthracyclines (as part of an induction regimen) in 128 newly diagnosed FLT3-ITD-mutated AML patients. Induction regimens comprised high-dose daunorubicin (HD-DN; 90 mg/m(2)/dx3d; n = 44), standard-dose daunorubicin (SD-DN; 45 mg/m(2)/dx3d; n = 51), or idarubicin (IDA; 12 mg/m(2)/dx3d; n = 33) in combination with cytarabine (100-200 mg/m(2)/dx7d). Fifty-three patients showing persistent leukemia on interim bone marrow examination received a second course of induction chemotherapy comprising 2 days of daunorubicin (45 mg/m(2)/d) or IDA (8 or 12 mg/m(2)/d) in addition to 5 days of cytarabine. Complete remission (CR) rates were 77.3%, 56.9%, and 69.7% for HD-DN, SD-DN, and IDA, respectively (P = 0.101; HD-DN vs. SD-DN, P = 0.036; HD-DN vs. IDA, P = 0.453; IDA vs. SD-DN, P = 0.237). The HD-DN showed higher overall survival (OS) and event-free survival (EFS) than SD-DN and IDA: the differences between HD-DN and SD-DN (P = 0.009 for OS and P = 0.010 for EFS) were statistically significant. Results of in vitro studies using FLT3-ITD-mutated cell lines supported these findings. In conclusion, HD-DN improved the CR rate, OS, and EFS of FLT3-ITD-mutated AML patients. HD-DN also tended to yield better outcomes than IDA, though the difference was not significant. The superiority of HD-DN over IDA should be confirmed in future studies.

引用

页码：51 / 56

页数：6

共 22 条

[1] Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia [J].

Burnett, Alan K. ;

Russell, Nigel H. ;

Hills, Robert K. .

BLOOD, 2016, 128 (03) :449-452

[2] A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients [J].

Burnett, Alan K. ;

Russell, Nigel H. ;

Hills, Robert K. ;

Kell, Jonathan ;

Cavenagh, Jamie ;

Kjeldsen, Lars ;

McMullin, Mary-Frances ;

Cahalin, Paul ;

Dennis, Mike ;

Friis, Lone ;

Thomas, Ian F. ;

Milligan, Don ;

Clark, Richard E. .

BLOOD, 2015, 125 (25) :3878-3885

[3]

Burnett AK, 2014, BLOOD, V124

[4] The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia [J].

Fathi, Amir T. ;

Chen, Yi-Bin .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (04) :330-336

[5] Anthracycline Dose Intensification in Acute Myeloid Leukemia [J].

Fernandez, Hugo F. ;

Sun, Zhuoxin ;

Yao, Xiaopan ;

Litzow, Mark R. ;

Luger, Selina M. ;

Paietta, Elisabeth M. ;

Racevskis, Janis ;

Dewald, Gordon W. ;

Ketterling, Rhett P. ;

Bennett, John M. ;

Rowe, Jacob M. ;

Lazarus, Hillard M. ;

Tallman, Martin S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1249-1259

[6] A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].

GRAY, RJ .

ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154

[7] A rapid, one step assay for simultaneous detection of FLT3/ITD and NPM1 mutations in AML with normal cytogenetics [J].

Huang, Qin ;

Chen, Wengang ;

Gaal, Karl K. ;

Slovak, Marilyn L. ;

Stein, Anthony ;

Weiss, Lawrence M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (03) :489-492

[8]

Kiyoi H, 2015, NAGOYA J MED SCI, V77, P7

[9] A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML [J].

Knapper, Steven ;

Russell, Nigel ;

Gilkes, Amanda ;

Hills, Robert K. ;

Gale, Rosemary E. ;

Cavenagh, James D. ;

Jones, Gail ;

Kjeldsen, Lars ;

Grunwald, Michael R. ;

Thomas, Ian ;

Konig, Heiko ;

Levis, Mark J. ;

Burnett, Alan K. .

BLOOD, 2017, 129 (09) :1143-1154

[10]

Lee J. H., 2015, BLOOD, V126, P2535

← 1 2 3 →